VEGFA and diabetic macular edema: In an open-label, multi-center, single dose escalation phase I study for diabetic macular edema (DME) patients who responded to prior anti-VEGF and/or corticosteroid, THR-687 intravitreal injections demonstrated a BCVA gain of 11.2 letters at week 2, and a lasting effect until month 3 with no toxicities or serious adverse events being noticed (ClinicalTrials.gov Identifier: NCT03666923) [66].